The contribution of non-drug factors to fetal malformation in anti-seizure-medication-treated pregnancy

Basit Öğe Kaydı
dc.authoridTaskiran, Ahmet Sevki/0000-0002-5810-8415
dc.contributor.authorFiliz, Ahmet Kemal
dc.contributor.authorGumus, Erkan
dc.contributor.authorKarabulut, Sebahattin
dc.contributor.authorTastemur, Yasar
dc.contributor.authorTaskiran, Ahmet Sevki
dc.date.accessioned2024-10-26T18:07:42Z
dc.date.available2024-10-26T18:07:42Z
dc.date.issued2021
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractPurpose: To assess the possible contribution of factors in additional to intrauterine anti-seizure medication (ASM) exposure in the occurrence of fetal malformation in women with ASM-treated epilepsy. Results: Logistic regression analysis showed that maternal age over 31 years, family histories of fetal malformation, and conception after assisted fertility treatment, and also dosage of valproate, carbamazepine, and topiramate, made statistically significant (P < 0.05) contributions to the fetal malformation rate in 2223 pregnancies in Australian women with epilepsy. The malformation rates were lower in pregnancies where the non-ASM-associated contributory factors were not present: statistically significantly so for all ASM-exposed pregnancies, and those pregnancies exposed to the more potent teratogenic drugs. Conclusion: It is important to consider the possible roles of identified, and also possible non-identified, non-ASM factors in relation to the occurrence of fetal malformations in the pregnancies of women with ASM-treated epilepsy. (C) 2021 Elsevier Inc. All rights reserved.
dc.description.sponsorshipThe Epilepsy Society of Australia; The Royal Melbourne Hospital Neuroscience Foundation; Epilepsy Action; NHMRC; Sanofi-Aventis; UCB Pharma; JanssenCilag; Novartis; Sci-Gen; Eisai; Genzyme
dc.description.sponsorshipWe wish to thank professional and lay colleagues who referred patients to the APR, and the APR's Scientific Advisory Board. The Research Ethics Committees of St. Vincent's Hospital, Monash Medical Centre, the Royal Melbourne Hospital and other institutions are thanked for continuing ethics oversight of the APR. Over the years, financial support for the Register has been provided by The Epilepsy Society of Australia, The Royal Melbourne Hospital Neuroscience Foundation, Epilepsy Action, the NHMRC and the pharmaceutical companies Sanofi-Aventis, UCB Pharma, JanssenCilag, Novartis, Sci-Gen, Eisai and Genzyme.
dc.identifier.issn1525-5050
dc.identifier.issn1525-5069
dc.identifier.urihttps://hdl.handle.net/20.500.12418/29645
dc.identifier.volume118
dc.identifier.wosWOS:000647685700041
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherAcademic Press Inc Elsevier Science
dc.relation.ispartofEpilepsy & Behavior
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAge
dc.subjectAnti-seizure medications
dc.subjectFetus
dc.subjectMalformation
dc.subjectNon-drug factors
dc.subjectTeratogenesis
dc.titleThe contribution of non-drug factors to fetal malformation in anti-seizure-medication-treated pregnancy
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu